Diagnosis of Schaaf-Yang syndrome in Korean children with developmental delay and hypotonia

Hyunj Ahn, MD, Go Hun Seo, MD, PhD, Arum Oh, MD, PhD, Yena Lee, MD, Changwon Keum, PhD, Sun Hee Heo, MSc, Taeho Kim, PhD, Jeongmin Choi, BSc, Gu-Hwan Kim, PhD, Tae-Sung Ko, MD, PhD, Mi-Sun Yum, MD, PhD, Beom Hee Lee, MD, PhD, In Hee Choi, PhD.

Abstract

Schaaf-Yang syndrome (SYS) is a recently identified disorder caused by a loss-of-function mutation in a maternally imprinted gene, MAGE\(_L\)2, at 15q11.2q13. Due to its extreme rarity and wide range of clinical severity, clinical suspicion is difficult for a physician. In the current study, its frequency among the Korean pediatric patients with developmental delay (DD) or intellectual disability (ID) was assessed. As the first report of Korean patients with SYS, our study aims to increase the awareness of this condition among the physicians taking care of the pediatric patients with DD/ID and hypotonia.

The patients diagnosed with SYS by whole-exome sequencing (WES) among the 460 Korean pediatric patients with DD/ID were included, and their clinical and molecular features were reviewed.

Four patients (0.9%) were diagnosed with SYS. Profound DD (4 patients), multiple anomalies including joint contractures and facial dysmorphism (4 patients), generalized hypotonia (3 patients), and severe respiratory difficulty requiring mechanical ventilation (3 patients) were noted in most cases, similar to those in previous reports. Sleep apnea (2 patients), autistic features (2 patients), a high grade of gastroesophageal reflux (1 patient), and seizures (1 patient) were found as well. A total of 3 different truncating MAGE\(_L\)2 mutations were identified. A previously-reported mutation, to be the most common one, c.1996dupC, was found in 2 patients. The other 2 mutations, c.2217delC and c.3449_3450delTT were novel mutations. As MAGE\(_L\)2 is maternally imprinted, 2 patients had inherited the MAGE\(_L\)2 mutation from their respective healthy fathers.

SYS is an extremely rare cause of DD/ID. However, hypotonia, joint contractures, profound DD/ID and facial dysmorphism are the suggestive clinical features for SYS. As a maternally imprinted disorder, it should be reminded that SYS may be inherited in form of a mutation from a healthy father.

Abbreviations: ACMG = American College of Medical Genetics, ASD = autism spectrum disorder, DD = developmental delay, ID = intellectual disability, IRB = Institutional Review Board, MAGE\(_L\)2 = melanoma-antigen-subfamily-like-2, MRI = magnetic resonance imaging, PWS = Prader–Willi Syndrome, SYS = Schaaf-Yang syndrome, WES = whole-exome sequencing.

Keywords: genomic imprinting, MAGE\(_L\)2, Schaaf-Yang syndrome

1. Introduction

The gene MAGE\(_L\)2 is one of the protein-coding genes located on the Prader–Willi syndrome (PWS; OMIM #176270) domain at chromosome 15q11-q13. This chromosomal region is an imprinting region, and MAGE\(_L\)2 is a maternally imprinted gene encoding the melanoma-antigen-subfamily-like-2 protein.\(^1\) MAGEL2 is part of a large ubiquitin complex that controls endocytosis, receptor recycling, and cell-surface localization.\(^1\) The paternal genomic deletion or maternal uniparental disomy at 15q11-13 are responsible for PWS, whereas pathogenic intragenic MAGEL2 mutations result in phenotypes of the Schaaf-Yang syndrome (SYS; OMIM #615447).\(^2\)

Editor: Muhammad Tarek Abdel Ghafar.

This work was supported by the Institute for Information & Communications Technology Promotion (IITP) and by a grant from the government of South Korea (MSIT) (grant number 2018-0-00861; Intelligent SW Technology Development for Medical Data Analysis) and by the Korea Brain Bank operated through the National Brain Bank Project funded by the Ministry of Science and ICT in 2019.

This study was approved by the Institutional Review Board (IRB) of Asan Medical Center (IRB 2018-0180, 2018-0574, and 2017-0988).

The authors have no potential conflicts of interest to disclose.

All data generated or analyzed during this study are included in this published article [and its supplementary information files].

* Department of Pediatrics, Asan Medical Center Children’s Hospital, University of Ulsan College of Medicine, **3billion, Inc., **ASAN Institute for Life Sciences, **Medical Genetics Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.

Correspondence: In Hee Choi, Medical Genetics Center, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul 05550, South Korea [e-mail: ina@amc.seoul.kr].

Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc.

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and build upon the work provided it is properly cited. The work cannot be used commercially without permission from the journal.

How to cite this article: Ahn H, Seo GH, Oh A, Lee Y, Keum C, Heo SH, Kim T, Choi J, Kim GH, Ko TS, Yum MS, Lee BH, Choi IH. Diagnosis of Schaaf-Yang syndrome in Korean children with developmental delay and hypotonia. Medicine 2020:99:51(e23864). Received: 19 June 2020 / Received in final form: 18 November 2020 / Accepted: 20 November 2020

http://dx.doi.org/10.1097/MD.0000000000023864
maternal imprinting pathway of MAGEL2 must be considered when interpreting its variants regarding parental inheritance. [3]

In 2013, Schaaf et al reported the first 4 patients with truncating mutations in the paternal copy of MAGEL2. [3] The phenotypic characteristics of these patients partially resembled those of patients with PWS; these characteristics include neonatal hypotonia, feeding problems, delayed development (DD), and intellectual disability (ID) and were referred to as “PW-like syndrome.” [3] With increasing numbers of individuals with pathogenic truncating variants of MAGEL2, their distinct phenotypic profile can be identified more reliably. Compared to PWS patients, SYS patients have higher incidences of autism spectrum disorder (ASD) and arthrogryposis. [4, 5] Moreover, SYS patients are characterized by a wide phenotypic spectrum despite numerous common clinical symptoms including varying degrees of ID and of language and motor development. [3–5]

The prevalence of SYS is unknown. By SEP 2020, only more than 120 individuals with pathogenic variants of MAGEL2 were reported worldwide. [2–18] Due to the small number of reported cases, the underlying pathological mechanisms and genotype-phenotype correlation in MAGEL2-related disorders remain to be elucidated. Moreover, clinical suspicion for SYS is not easy in pediatric patients with hypotonia and DD/ID due to physicians’ unfamiliarity.

Here we report the first 4 Korean SYS patients with MAGEL2-intragenic mutations, which was found in 0.9% out of the pediatric patients with DD/ID. The clinical features of these patients with SYS were described in detail. The Mutations were identified in all 4 cases by whole-exome sequencing (WES), which was confirmed by family member testing. The 2 mutations were novel. Our report aims to increase the awareness of this condition among the physicians taking care of the pediatric patients with DD/ID and hypotonia.

2. Methods

2.1. Patients

Patients (age < 19 years) who had DD/ID and undiagnosed with chromosomal analysis and routine metabolic work-up such as plasma amino acid analysis, plasma acylcarnitine analysis, and urine organic analysis at the Asan Medical Center Children’s Hospital, Seoul, Korea underwent WES as in Figure 1. Among them, the patients diagnosed with SYS were included in this study. The cognitive, neurological, developmental, and physical spectrum of phenotypes using data were reviewed with their medical records.

2.2. Genetic analyses

Informed consent for genetic testing was obtained from patients or their legal guardians. WES was performed using genomic DNA isolated from either whole blood or saliva. All exons of all human genes (approximately 22,000) were captured using a SureSelect kit (Version C2; Agilent Technologies, Inc., Santa Clara, CA, USA). The captured genomic regions were sequenced using a NovaSeq platform (Illumina, San Diego, CA, USA). Raw genome sequencing data analyses included alignment to the reference sequence (NCBI genome assembly GRCh37; accessed in February 2009). Mean depth of coverage was 100-fold with 99.2% coverage higher than 10-fold. Variant calling, annotation, and prioritization were performed as previously described. [19] In brief, the similarity between patient’s phenotype and symptoms associated with disease caused by prioritized variants according to the American College of Medical Genetics (ACMG) guidelines [20, 21] was integrated and automated by all computational process. [19]

For MAGEL2 gene sequencing, genomic DNA was isolated from peripheral blood using PUREGENE DNA isolation kit (Qiagen, Hilden, Germany). The MAGEL2 gene was amplified by PCR using primers designed with primer3 cgi v.3.0, Whitehead Institute (http://bioinfo.ut.ee/primer3-0.4.0/) and a reference sequence (NCBI GenBank accession number NT_026446.14). The PHOX2B gene was amplified exon-by-exon including promoter region by PCR using primers designed with primer3 and NT_006238.11 as reference sequence. To analyze whole mitochondrial sequence, 24 parts of the mitochondrial DNA were amplified by PCR using primers by Rieder et al. [22] DNA sequencing was performed using a BigDye Terminatore V3.1 Cycle Sequencing Ready reaction kit (Applied Biosystems, Foster City, CA, USA) according to the manufacturer’s instructions.

To analyze (CTG)n expansion of DMPK gene, PCR was performed by use of the primers 5'-CAGTTCACAACCGCTCC-GAGC-3' and 5'-CGTGGAGATGGAACACGGAC-3'. Subsequently PCR-Southern blot was performed using biotin-labeled (CTG)10 probe (COSMO genetech, Japan) and the DNA-Detector Southern blotting kit (KPL, Maryland, USA). To analyze (CAG)n expansion of FMR1 gene, AmpliDex PCR/CE FMR1 (Asurgen, Austin, TX, USA) was used according to the manufacturer’s instructions.

This study was approved by the Institutional Review Board (IRB) of Asan Medical Center (IRB 2018-0180, 2018-0574, and 2017-0988).

3. Results

Among the 460 Korean individuals subjected to WES due to DD/ID, 4 individuals (0.9%) were diagnosed with SYS due to a mutation in the MAGEL2 gene.

The clinical and genetic features were described in Table 1.
3.1. Clinical characteristics of 4 patients with SYS

3.1.1. Patient #1. The patient was the second child of healthy, non-consanguineous Korean parents. At the time of his birth, the mother was 41 years old. After an uneventful pregnancy, the boy was born at term by vaginal delivery and weighed 3270 g (percentile 13.0) with a length of 50 cm (percentile 15.1) and head circumference of 36 cm (percentile 27.2). No family history of neurological diseases existed apart from cloacal anomaly in the patient’s sister. After birth, dysmorphic features were observed including frontal bossing, prominent ears, sparse hair and eyebrows, inverted nipples, distal arthrogyrosis, club feet, and small hands and feet. Neurological examination revealed severe global hypotonia with retained reflexes. During the first week of life, the patient needed oxygen and mechanical ventilation therapy owing to recurrent apnea. Strength of sucking was weak, and nasogastric-tube feeding was required during the first 1.5 months of life. Brain magnetic resonance imaging (MRI) revealed asymmetrical lateral ventricles with a mildly dysmorphic shape (Fig. 2); however, no other parenchymal lesions were observed. Abdominal ultrasound and metabolic screening were normal. His thyroid function was normal. The patient was able to stand with support at 11 months of age but was not able to stand without support until aged 36 months (Table 2). At the most recent follow-up at age 38 months, he did not utter any meaningful words and presented autistic features. Body height and head circumference were persistently below the 3rd percentile.

3.1.2. Patient #2. The patient was the first-born of twins born after in-vitro fertilization and had healthy, non-consanguineous parents. At the time of giving birth, the mother was 43 years old. The boy was born at 37 weeks of gestation by cesarean section and weighed 2530 g (below the 3rd percentile). A highly arched palate, severe camptodactyly of the 1st, 3rd, 4th, and 5th fingers of both hands, and bilateral equinovarus were observed. After birth, the patient experienced numerous apneic episodes and needed respiratory assistance. Brain MRI showed a minimally dysmorphic lateral ventricle without dilatation (Fig. 2). Laryngoscopy produced a laryngeal cleft type 1 and vocal cord palsy, and polysomnography revealed severe obstructive sleep apnea. In addition, a nasogastric-tube was installed due to poor sucking, recurrent vomiting, decreased gastrointestinal motility, and severe gastro-esophageal reflux. Laparoscopic pyloromyotomy was performed at 2 months of age. Until aged 6 months, the patient suffered from intermittent apneic episodes and required tube feeding. His thyroid function was normal. Body height, weight, and head circumference were below the 3rd percentile, and the boy was unable to support his head (Table 2).

3.1.3. Patient #3. The patient was the fourth child of healthy, non-consanguineous 34-year-old parents. The pregnancy was spontaneous. The prenatal period was complicated by polyhydramnios, and his weight at birth was 3600 g (70th percentile). The patient had 3 healthy sisters. After birth, he experienced respiratory failure requiring resuscitation. Generalized hypotonia was noted, with dysmorphic features including a coarse face, flat nasal root, large ears, camptodactyly of the 3rd, 4th, and 5th fingers, clinodactyly, and cryptorchidism. He was able to support his head at 6 months of age, sat upright with support at age 10 months, stood with support at age 14 months, and walked without support at 35 months of age. The patient uttered his first meaningful word at age 36 months (Table 2). At the most recent evaluation at age 47 months, his height was in the 25th percentile.

Table 1

Molecular and clinical phenotypes of 4 individuals with truncating MAGEL2 mutations.

| Sex                        | Patient #1 male | Patient #2 male | Patient #3 male | Patient #4 female | Previous publications |
|----------------------------|-----------------|-----------------|-----------------|-------------------|----------------------|
| Disease onset age          | 0 months        | 0 months        | 0 months        | 19 months         |                      |
| Molecular diagnosis        |                 |                 |                 |                   |                      |
| Mutation Nucleotide        | c.1996dupC      | c.1996dupC      | c.2217delC      | c.3449_3450delTT  |                      |
| Protein                    | p.Gln666ProfsTer47 | p.Gln666ProfsTer47 | p.Ser739Ter    | p.Phe1150TrpfsTer4 |                      |
| Inheritance                | Reported        | Reported        | Not reported    | Not reported      |                      |
| Prenatally problem         |                 |                 |                 |                   |                      |
| History of polyhydramnios  |                 |                 |                 |                   | N/A                  |
| Postnatal difficulties     |                 |                 |                 |                   |                      |
| Neonatal hypotonia         |                 |                 |                 |                   | 97%                  |
| Respiratory distress       |                 |                 |                 |                   | 55%                  |
| Mechanical ventilator      |                 |                 |                 |                   | 84%                  |
| Clinical phenotypes        |                 |                 |                 |                   |                      |
| Facial dysmorphism         |                 |                 |                 |                   | 81%                  |
| Joint contractures         |                 |                 |                 |                   | 88%                  |
| Macrocephaly               |                 |                 |                 |                   | N/A                  |
| Microcephaly               |                 |                 |                 |                   | N/A                  |
| Brain MR abnormality       |                 |                 |                 |                   |                      |
| Developmental problems     |                 |                 |                 |                   |                      |
| Central sleep apnea        |                 |                 |                 |                   | 76%                  |
| Gastroesophageal reflux    |                 |                 |                 |                   | 57%                  |
| Chronic constipation       |                 |                 |                 |                   | 71%                  |
| Failure to thrive          |                 |                 |                 |                   | N/A                  |
| Delayed development/intellectual disability |                 |                 |                 |                   | 100%                 |
| Autistic features          |                 |                 |                 |                   | 78%                  |
| Seizures                   |                 |                 |                 |                   | 33%                  |

N/A = information not provided or otherwise unavailable.
weight was in the 75th percentile, and head circumference was in the 25th percentile. His thyroid function and blood sugar levels were normal. He could not utter a two-word sentence and exhibited autism spectrum disorder and experienced generalized nonmotor absence seizures.

3.1.4. Patient #4. The female patient had healthy, non-consanguineous 31-year-old parents and a healthy younger brother. The girl was born at term with a weight of 3070g (28th percentile). The pregnancy was spontaneous. She stood without support at age 17 months and walked without support at age 20 months. She uttered the first meaningful word at age 24 months but was not able to pronounce a two-word sentence until aged 34 months (Table 2). At 34 months, her height was in the 75th percentile, and weight and head circumference were in the 97th percentile. Hypertelorism and thick eyebrows were observed. Brain MRI did not reveal any significant abnormal findings. Her thyroid function and blood sugar levels were normal.

3.2. Molecular genetic analyses

All 4 patients showed normal karyotypes. To identify potential genetic causes for DD with hypotonia and respiratory difficulties, the mitochondrial genome of patient #1, the gene PHOX2B of patient #2, the DMPK gene of patient #2, and the FMR1 gene of patient #4 were sequenced; however, no mutation was observed. WES was performed at ages 12 months (patient #1), 1 month (patient #2), 30 months (patient #3), and 19 months (patient #4). WES yielded 111,390 (range, 105,155–114,769) variants on average in each patient. After filtering-out variants with frequency of 5% or higher of minor allele frequency, approximately 10,996 (10,313–11,429) variants on average were remained in each patient. After excluding variant with low impact including likely benign, benign, and non-coding variant with low evidence according to the ACMG guidelines and filtering by known inheritance pattern and gene matched with known disease up to date, 51 (41–64) disease-variant pairs on average remained. Finally, candidate genetic variants were

Table 2
Developmental outcomes of the 4 patients with Schaaf-Yang syndrome.

| Developmental outcomes        | Patient #1 | Patient #2 | Patient #3 | Patient #4 |
|-------------------------------|------------|------------|------------|------------|
| Age at most recent examination (Dec 2019) | 38 months | 6 months   | 47 months  | 36 months  |
| Motor development             |            |            |            |            |
| Head control                  | 5 months   | x          | 6 months   | NA         |
| Roll-over                     | 9 months   |            | 7 months   | NA         |
| Sit alone with tripod          | 7 months   |            | 10 months  | NA         |
| Stand with support            | 11 months  |            | 14 months  | NA         |
| Standing independently         | x          |            | 17 months  | 17 months  |
| Walking independently         | x          |            | 35 months  | 20 months  |
| Language development          |            |            |            |            |
| First word                    | x          |            | 36 months  | 24 months  |
| First two-word sentence       | x          |            | x          | x          |

N/A = information not provided or otherwise unavailable.
selected based on the relationship between the gene and patient phenotypes, and only the variants in the \textit{MAGEL2} gene (NM_019066.4) remained.

All patients had a heterozygous truncating variant in the \textit{MAGEL2} gene, which was c.1996\_dupC (p.Gln666ProfsTer47) in patients \#1 and \#2, c.2217\_delC (p.Ser739Ter) in patient \#3, and c.3449_3450\_delTT (p.Phe1150TrpfsTer4) in patient \#4. The variant c.1996\_dupC has been previously described,[2,5\_8,11,14,15] whereas c.2217\_delC and c.3449_3450\_delTT have never been reported. The allele frequency of p.Gln666ProfsTer47 was 0.002\% in gnomAD (https://gnomad.broadinstitute.org/); however, those of p.Phe1150TrpfsTer4 and p.Ser739Ter have not been reported previously. p.Gln666ProfsTer47 is classified as a "pathogenic" variant, and p.Ser739Ter and p.Phe1150TrpfsTer4 are categorized as "likely pathogenic" variants, according to the ACMG Guidelines.[23] All variants observed in the present study were confirmed by Sanger sequencing. The variants were not detected in DNA isolated from peripheral leukocytes of the parents of patients \#2 and \#3, whereas the fathers of patients \#1 and \#4 were heterozygous for the respective variant (Fig. 3).

There was no other mutation in 59 medically actionable genes for secondary reporting recommended by ACMG guidelines.[24]

4. Discussion
The current study describes the first Korean SYS patients. SYS is an ultra-rare genetic disorder with unknown prevalence.[2\_18] In our patient cohort, 0.9\% of patients with DD/ID can be expected to suffer from SYS.

As the first report of SYS in Korean population, although only 4 patients are described, our report helps to understand the common clinical and genetic characteristics among the affected patients. Clinical manifestations in the 4 patients were similar to those described in previous reports (table 1).[2\_4,5] The 3 male infants showed generalized hypotonia, severe respiratory difficulty requiring mechanical ventilation, profound DD, and multiple anomalies including joint contractures and facial dysmorphism from birth. The girl presented slightly delayed motoric and language development and mild dysmorphic characteristics. Also, feeding problems requiring nasogastric tube feeding, gastro-esophageal reflux, chronic constipation, and failure to thrive were noted. Furthermore, neuropsychiatric symptoms such as autism and seizures were observed. The patients showed either micro- or macrocephaly. Brain imaging revealed asymmetrical lateral ventricles with mild dysmorphic shape.

SYS has been referred to as "PW-like syndrome" as SYS and PWS share major clinical symptoms such as neonatal hypotonia, feeding difficulties, failure to thrive, respiratory distress, and DD/ID.[25,26] However, joint contractures and higher prevalence of life-threatening respiratory distress are more commonly observed in SYS than in PWS.[5] During childhood, ASD is more common in SYS,[4] and SYS patients generally do not exhibit over-eating habits with severe obesity as do PWS patients.[25\_27] Most SYS patients exhibit DD/ID[5]; however, the level of ID varies substantially from mild to profound.[5] On average, children with SYS were able to sit independently at age 18 months, to crawl at 31 months, and to walk independently at 30 months. Previously, SYS patients were found to utter their first word at 36 months.

![Figure 3](https://example.com/figure3.png)

**Figure 3.** Family tree of 4 patients with Schaaf-Yang syndrome (SYS). In patients \#1 (A) and \#2 (B), a heterozygous frameshift mutation, c.1996\_dupC, was detected. Two novel mutations were detected in patient \#3 (C; c.2217\_delC) and patient \#4 (D; c.3449_3450\_delTT). The respective fathers of patients \#1 and \#4 were heterozygous for the respective mutations.
months and use first two-word sentences at 40 months of age.\textsuperscript{[4]} However, not all clinical characteristics necessarily occur in every patient. In our case series, patient #4 only showed motoric DD and signs of autism but no other symptoms.

A recent study showed that phenotypic severity may depend on the respective location of the truncating mutation, suggestive a genotype-phenotype association.\textsuperscript{[5]} In the largest number of cases, as reviewed by McCarthy et al, approximately half the maternal allele, which is silenced (Fig. 3). No difference in terms of causes intrauterine fetal or perinatal demise.\textsuperscript{[5]} Thus far, the precise pathomechanisms of SYS have yet to be elucidated. Further identification and investigation of cases with MAGEL2 mutations will help understand the pathogenic mechanisms and genotype-phenotype correlations of SYS.

There are some limitations to our study. Due to the small number of patients, our report does not represent the general clinical and genetic features of SYS patients in Korean population. With more cases identified, the full spectrum of clinical and genetic features of SYS needs to be understood in the perspectives of ethnic background.

5. Conclusions
SYS is an extremely rare genetic disorder with a variety of musculoskeletal and neurodevelopmental phenotypes, accounting for 0.9% of DD/ID. However, hypotonia, joint contractures, DD/ID and facial dysmorphism are the suggestive clinical features for SYS. As a maternally imprinted disorder, it should be reminded that SYS may be inherited in form of a mutation from a healthy father. After this first report of SYS in the Korean population, identification of more cases will help understand the clinical and molecular characteristics of this extremely rare genetic condition among the different ethnic groups.

Acknowledgments
We deeply appreciate the patients and their families for participating in this study.

Author contributions
Conceptualization: Tae-Sung Ko.

Data curation: Hyunji Ahn, Go Hoon Seo, Arum Oh, Yena Lee, Sun Hee Heo, Taeho Kim, Jeongmin Choi, Beom Hee Lee.

Formal analysis: Changwon Keum, Sun Hee Heo, Taeho Kim, Gu-Hwan Kim, In Hee Choi.

Methodology: Go Hun Seo, In Hee Choi.

Supervision: Tae-Sung Ko, Beom Hee Lee.

Validation: Go Hun Seo, Taeho Kim, Jeongmin Choi, In Hee Choi.

Writing – original draft: Hyunji Ahn, Taeho Kim, Jeongmin Choi, Mi-Sun Yum, In Hee Choi.

Writing – review & editing: Arum Oh, Yena Lee, Changwon Keum, Sun Hee Heo, Tae-Sung Ko, Mi-Sun Yum, Beom Hee Lee, In Hee Choi.

References
\[1\] Doyle JM, Gao J, Wang J, et al. MAGE-RING protein complexes comprise a family of E3 ubiquitin ligases. Mol Cell 2010;39:963–74.
\[2\] Patak J, Gilbert J, Byler M, et al. MAGEL2-related disorders: a study and case series. Clin Genet 2019;96:493–505.
\[3\] Schaaf CP, Gonzalez-Garay ML, Xia F, et al. Truncating mutations of MAGEL2 cause Prader-Willi phenotypes and autism. Nat Genet 2013;45:1405–8.
\[4\] Fountain MD, Aten E, Cho MT, et al. The phenotypic spectrum of Schaaf-Yang syndrome: 18 new affected individuals from 14 families. Genet Med 2017;19:45–52.
\[5\] McCarthy J, Lupo PJ, Kovar E, et al. Schaaf-Yang syndrome overview: Report of 78 individuals. Am J Med Genet A 2018;176:2564–74.
\[6\] Soden SE, Saunders CJ, Willig LK, et al. Effectiveness of exome and genome sequencing guided by acuity of illness for diagnosis of neurodevelopmental disorders. Sci Transl Med 2014;6:233ra168.
\[7\] Mejala S, Dinh V, Malureau J, et al. Truncating Mutations of MAGEL2, a gene within the Prader-Willi Locus, are responsible for severe arthrogryposis. Am J Hum Genet 2015;97:616–20.
\[8\] Palomares-Bralo M, Vallespin E, Del Pozo A, et al. Pitfalls of trio-based exome sequencing: imprinted genes and parental mosaicism-MAGEL2 as an example. Genet Med 2017;19:1285–6.
\[9\] Urreizti R, Cueto-Gonzalez AM, Franco-Valls H, et al. A de novo nonsense mutation in MAGEL2 in a patient initially diagnosed as Opitz-C syndrome: similarities between Schaaf-Yang and Opitz-C syndromes. Sci Rep 2017;7:44138.
\[10\] Enya T, Okamoto N, Iba Y, et al. Three patients with Schaaf-Yang syndrome exhibiting arthrogryposis and endocrinological abnormalities. Am J Med Genet A 2018;176:707–11.
\[11\] Bayat A, Bayat M, Loroya R, et al. Chronic intestinal pseudo-obstruction syndrome and gastrointestinal malrotation in an infant with schaaf-yang syndrome - expanding the phenotypic spectrum. Eur J Med Genet 2017;61:627–30.
\[12\] Matuszewska KE, Badura-Stronika M, Smigiel R, et al. Phenotype of two Polish patients with Schaaf-Yang syndrome confirmed by identifying mutation in MAGEL2 gene. Clin Dysmorphol 2018;27:49–52.
\[13\] Jobling R, Stavropoulos DJ, Marshall CR, et al. Chitayat-Hall and Schaaf-Yang syndromes: a common aetiology: expanding the phenotype of MAGEL2-related disorders. J Med Genet 2018;55:316–21.
\[14\] Tong W, Wang Y, Lu Y, et al. Whole-exome sequencing helps the diagnosis and treatment in children with neurodevelopmental delay accompanied unexplained dyspnea. Sci Rep 2018;8:5214.
\[15\] Negishi Y, Ieda D, Hori I, et al. Schaaf-Yang syndrome shows a Prader-Willi syndrome-like phenotype during infancy. Orphanet J Rare Dis 2019;14:277.
\[16\] Powell WT, Schaaf CP, Rech ME, et al. Polysomnographic characteristics and sleep-disordered breathing in Schaaf-Yang syndrome. Pediatr Pulmonol 2020;53:2464–20.
\[17\] Chen X, Ma X, Zou C. Phenotypic spectrum and genetic analysis in the fatal cases of Schaaf-Yang syndrome: two case reports and literature review. Medicine (Baltimore) 2020;99:e20574.
\[18\] Xiao B, Ji X, Wei W, et al. A recurrent variant in MAGEL2 in five siblings with severe respiratory disturbance after birth. Mol Syndromol 2020;10.1002/ppul.25056.
\[19\] Bögg LS, Adams M, Nasser N, et al. An informatics approach to analyzing the incidentalome. Genet Med 2013;15:36–44.
[21] Berg JS, Khoury MJ, Evans JP. Deploying whole genome sequencing in clinical practice and public health: meeting the challenge one bin at a time. Genet Med 2011;13:499–504.

[22] Rieder MJ, Taylor SL, Tobe VO, et al. Automating the identification of DNA variations using quality-based fluorescence re-sequencing; analysis of the human mitochondrial genome. Nucleic Acids Res 1998;26:967–73.

[23] Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;17:405–24.

[24] Kalia SS, Adelman K, Bale SJ, et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics. Genet Med 2017;19:249–55.

[25] Baran M, Celikkalkan K, Cagan Appak Y, et al. Body fat mass is better indicator than indirect measurement methods in obese children for fatty liver and metabolic syndrome. SciMedicine J 2019;1:74–111.

[26] Świerczynski A. Pathogenicity of endocrine dysregulation in autism: the role of the melanin-concentrating hormone system. SciMedicine J 2019;1:74–111.

[27] Davarani MN, Bnirostam T, Saberi H. Identification of autism disorder spectrum based on facial expressions. Emerg Sci J 2017;1:97–104.

[28] Mercer RE, Wevrick R. Loss of magel2, a candidate gene for features of Prader-Willi syndrome, impairs reproductive function in mice. PLoS One 2009;4:e4291.

[29] Bischof JM, Stewart CL, Wevrick R. Inactivation of the mouse Magel2 gene results in growth abnormalities similar to Prader-Willi syndrome. Hum Mol Genet 2007;16:2713–9.